Deferred treatment is a safe and viable option for selected patients with mantle cell lymphoma. Leuk Lymphoma 2018 Dec;59(12):2862-2870
Date
06/19/2018Pubmed ID
29912594Pubmed Central ID
PMC6360945DOI
10.1080/10428194.2018.1455973Scopus ID
2-s2.0-85048791473 (requires institutional sign-in at Scopus site) 11 CitationsAbstract
Prospective identification of candidates for deferred therapy is not standardized and many patients receive immediate therapy regardless of risk. We conducted a retrospective, multi-center cohort analysis of MCL patients with comprehensive clinical data to examine the use and safety of deferred therapy for newly diagnosed patients. Previously untreated patients ≥18 years-old with MCL diagnosed in 1993-2015 at five academic sites were included. Of 395 patients, 72 (18%) received deferred therapy (defined as receipt of first treatment >90 days following initial diagnosis). Patients receiving deferred therapy were more likely to have an ECOG performance status of 0 (67 versus 44% p = .001), have no B symptoms (83 versus 65% p = .003) and have normal LDH levels at diagnosis (87 versus 55% p < .001). In multivariable analysis, deferred therapy was not associated with a significant difference in OS (HR 0.64: 95% CI 0.22-1.84, p = .407).
Author List
Calzada O, Switchenko JM, Maly JJ, Blum KA, Grover N, Mathews S, Park SI, Gordon M, Danilov A, Epperla N, Fenske TS, Hamadani M, Flowers CR, Cohen JBAuthors
Timothy Fenske MD Professor in the Medicine department at Medical College of WisconsinMehdi H. Hamadani MD Professor in the Medicine department at Medical College of Wisconsin
MESH terms used to index this publication - Major topics in bold
AdultAged
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols
Disease Progression
Female
Humans
Lymphoma, Mantle-Cell
Male
Middle Aged
Patient Selection
Prospective Studies
Retrospective Studies
Severity of Illness Index
Survival Analysis
Time-to-Treatment
Watchful Waiting
